Monograph Details
|
|
Endocrine System
> Diabetes
|
|
MICRONASE |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Sulfonylurea (2nd generation). |
| Generic Name |
|
Glyburide 1.25mg, 2.5mg, 5mg; scored tabs. |
| Indications |
|
Adjunct to diet in type 2 diabetes. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 2.5–5mg daily with breakfast. Elderly, debilitated: initially 1.25mg daily with breakfast. Increase by 2.5mg at weekly intervals if needed per blood glucose. Maintenance: 1.25–20mg daily in single or divided doses (consider divided doses above 10mg daily); max 20mg daily. |
| Contraindications |
|
Ketoacidosis. Type I diabetes, as sole therapy. |
| Precautions |
|
Renal or hepatic impairment. Adrenal or pituitary insufficiency. Stress. Secondary failure. Monitor glucose. Discontinue if jaundice or persistent rash occurs. Avoid sun, UV light. Malnourished. Elderly. Debilitated. Pregnancy (Cat.B): consider using insulin instead. Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by NSAIDs, ciprofloxacin, miconazole, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, calcium channel blockers, isoniazid. Disulfiram-like reaction with alcohol (rare). Monitor for 2 wks if transferring from chlorpropamide. |
| Adverse Reactions |
|
Increased risk of cardiovascular mortality. Hypoglycemia, GI disturbances, allergic skin reactions, photosensitivity, SIADH, blood dyscrasias, hepatic porphyria; cholestatic jaundice (rare). |
| How Supplied |
Tabs 1.25mg, 2.5mg—100
5mg—30, 60, 100, 500, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
